Merck Millipore Announces Incoming CEO and President
News Apr 15, 2014
Dr. Batra will assume leadership effective May 15, 2014 and be based at the company’s U.S. headquarters in Massachusetts.
“As a global leader in the Life Sciences industry, I am very humbled and excited to be a part of Merck Millipore team and look forward to serving our customers globally,” Dr. Batra said. “As a former researcher who personally utilized the strong differentiated products that Merck Millipore offers, I have watched this organization develop over the past several years, and look forward to further building upon that success to bring continued value to our customers and other stakeholders.”
Dr. Batra comes to Merck Millipore from the Consumer Health division of Merck KGaA, where he successfully grew the business in established and emerging markets. He previously worked at Novartis Vaccines & Diagnostics, where he was Head of Global Public Health and Market Access. Prior to that, he served in a range of executive management positions at Novartis, including global Head of Corporate Strategy and Country President for the Pharma Business in Australia.
Dr. Batra started his career as a research engineer at Merck & Co. In 2001, he joined McKinsey where he worked across the healthcare, consumer and nonprofit sectors as a senior engagement manager. In 2004, he was appointed global Brand Director for the Wound Care Franchise at Johnson & Johnson, before joining Novartis in 2006.
Dr. Batra is a member of the WSMI (World Self Medication Industry) and the Chair of the Food Supplements Committee of the AESGP (Association of the European Self-Medication Industry).
He holds a Ph.D. in chemical engineering from Princeton University and a bachelor’s degree in chemical engineering from the University of Delaware.
Ancient Fish Genes May Hold Key to Spinal Cord RepairNews
A study has found that genes controlling spinal cord repair in the lamprey fish are also active in mammals, which could provide a blueprint for treatment.READ MORE
Researchers Develop Novel ‘One-pot’ Approach to Conjugated Tetraenes SynthesisNews
TUAT researchers have achieved the new synthetic route of conjugated tetraenes from inexpensive and easily available 1,3-butadiene and substituted acetylenes by a one-pot approach under mild conditions. Conjugated tetraenes are important key substructures in biologically active natural products such as vitamins, and anti-mycotic drugs.READ MORE
New Class of Drugs for the Treatment of Advanced Lung DiseaseNews
Researchers have demonstrated the potential of a new class of drugs for the treatment of refractory chronic obstructive pulmonary disease, i.e. COPD.READ MORE
Comments | 0 ADD COMMENT
Precision Medicine & Biomarkers Leaders Summit: USA
May 07 - May 08, 2018